114 related articles for article (PubMed ID: 20921578)
1. When to start antiretroviral therapy.
Kitahata MM
Top HIV Med; 2010; 18(3):121-6. PubMed ID: 20921578
[TBL] [Abstract][Full Text] [Related]
2. When to start antiretroviral therapy: a swinging pendulum?
Gallant JE
Top HIV Med; 2008; 16(2):82-8. PubMed ID: 18591715
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.
Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X
AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361
[TBL] [Abstract][Full Text] [Related]
4. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy.
Johnson SC
Top Antivir Med; 2016 Dec-2017 Jan; 23(5):161-7. PubMed ID: 27398769
[TBL] [Abstract][Full Text] [Related]
6. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
[TBL] [Abstract][Full Text] [Related]
7. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
8. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Geffen N; Aagaard P; Corbelli GM; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Collins S;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):10-3. PubMed ID: 25711318
[TBL] [Abstract][Full Text] [Related]
9. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
[TBL] [Abstract][Full Text] [Related]
10. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
11. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Dana T; Grusing S; Bougatsos C
JAMA; 2019 Jun; 321(23):2337-2348. PubMed ID: 31184705
[TBL] [Abstract][Full Text] [Related]
12. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
[TBL] [Abstract][Full Text] [Related]
13. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi.
Gitura B; Joshi MD; Lule GN; Anzala O
East Afr Med J; 2007 Oct; 84(10):466-72. PubMed ID: 18232267
[TBL] [Abstract][Full Text] [Related]
14. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
Sungkanuparph S; Anekthananon T; Hiransuthikul N; Bowonwatanuwong C; Supparatpinyo K; Mootsikapun P; Chetchotisakd P; Kiertiburanakul S; Tansuphaswadikul S; Buppanharun W; Manosuthi W; Techasathit W; Ratanasuwan W; Tantisiriwat W; Suwanagool S; Leechawengwongs M; Ruxrungtham K;
J Med Assoc Thai; 2008 Dec; 91(12):1925-35. PubMed ID: 19133532
[TBL] [Abstract][Full Text] [Related]
16. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
Loutfy MR; Genebat M; Moore D; Raboud J; Chan K; Antoniou T; Milan D; Shen A; Klein MB; Cooper C; Machouf N; Rourke SB; Rachlis A; Tsoukas C; Montaner JS; Walmsley SL; Smieja M; Bayoumi A; Mills E; Hogg RS;
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):451-9. PubMed ID: 21105259
[TBL] [Abstract][Full Text] [Related]
17. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
[TBL] [Abstract][Full Text] [Related]
19. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
20. Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts.
Nieuwkerk PT; Hillebrand-Haverkort ME; Vriesendorp R; Frissen PH; de Wolf F; Sprangers MA;
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):600-1. PubMed ID: 17704686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
